Modifications of therapeutic proteins: Challenges and prospects

Cytotechnology

Volumn 53, Issue 1-3, 2007, Pages 121-125

  Jenkins, Nigel ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Aggregation; Cell culture; Deamidation; Folding; Glycosylation; Oxidation; Recombinant protein; Therapeutics

Indexed keywords

ASPARAGINE; GLUTAMINE; IMMUNOGLOBULIN G; METHIONINE; RECOMBINANT PROTEIN;

CONFERENCE PAPER; DEAMINATION; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MODIFICATION;

EID: 34250642327     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-007-9075-2     Document Type: Conference Paper

References (35)

1. Baker KN, Rendall MH, Hills AE, Hoare M, Freedman RB, James DC (2001) Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol Bioeng 73:188-202
2. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2:326-332
3. Bragonzi A, Distefano G, Buckberry LD, Acerbis G, Foglieni C, Lamotte D, Campi G, Marc A, Soria MR, Jenkins N et al (2000) A new Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. Biochim Biophys Acta 1474:273-282
4. Capelle MA, Gurny R, Arvinte T (2007) High throughput screening of protein formulation stability: Practical considerations. Eur J Pharm Biopharm 65:131-148
5. Chakravarthi S, Jessop CE, Bulleid NJ (2006) The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep 7:271-275
6. Chelius D, Rehder DS, Bondarenko PV (2005) Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem 77:6004-6011
7. Chirino AJ, Mire-Sluis A (2004) Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22:1383-1391
8. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF (2001) A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90:310-321
9. Cudna RE, Dickson AJ (2003) Endoplasmic reticulum signaling as a determinant of recombinant protein expression. Biotechnol Bioeng 81:56-65
10. De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11:203-209
11. Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T (2007) Characterization of protein aggregation: the case of a therapeutic immunoglobulin. Biochim Biophys Acta 1774:146-153
12. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299
13. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I (2004) Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32:1146-1155
14. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93:851-861
15. Gu X, Wang DI (1998) Improvement of interferon-gamma sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosamine. Biotechnol Bioeng 58:642-648
16. Harris RJ (2005) Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) 122:117-127
17. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752:233-245
18. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903
19. Houde D, Kauppinen P, Mhatre R, Lyubarskaya Y (2006) Determination of protein oxidation by mass spectrometry and method transfer to quality control. J Chromatogr A 1123:189-198
20. Jenkins N, Parekh RB, James DC (1996) Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol 14:975-981
21. Koopmann JO, Blackburn J (2003) High affinity capture surface for matrix-assisted laser desorption/ionisation compatible protein microarrays. Rapid Commun Mass Spectrom 17:455-462
22. Lin JJ, Meyer JD, Carpenter JF, Manning MC (2000) Stability of human serum albumin during bioprocessing: denaturation and aggregation during processing of albumin paste. Pharm Res 17:391-396
23. Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter-Katalinic J (2003) Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng 83:321-334
24. Purohit VS, Middaugh CR, Balasubramanian SV (2006) Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95:358-371
25. Roach P, Woodworth JR (2002) Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 41:1043-1057
26. Schroder M, Schafer R, Friedl P (2002) Induction of protein aggregation in an early secretory compartment by elevation of expression level. Biotechnol Bioeng 78:131-140
27. Serrato JA, Palomares LA, Meneses-Acosta A, Ramirez OT (2004) Heterogeneous conditions in dissolved oxygen affect N-glycosylation but not productivity of a monoclonal antibody in hybridoma cultures. Biotechnol Bioeng 88:176-188
28. Sheridan C (2007) Commercial interest grows in glycan analysis. Nat Biotechnol 25:145-146
29. Soenderkaer S, Carpenter JF, van de Weert M, Hansen LL, Flink J, Frokjaer S (2004) Effects of sucrose on rFVIIa aggregation and methionine oxidation. Eur J Pharm Sci 21:597-606
30. Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, Levine RL (2000) Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 275:27258-27265
31. Tsumoto K, Ejima D, Kita Y, Arakawa T (2005) Review: Why is arginine effective in suppressing aggregation? Protein Pept Lett 12:613-619
32. Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24:1241-1252
33. Warnock D, Bai X, Autote K, Gonzales J, Kinealy K, Yan B, Qian J, Stevenson T, Zopf D, Bayer RJ (2005) In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase. Biotechnol Bioeng 92:831-842
34. Yang M, Butler M (2002) Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog 18:129-138
35. Ye H (2006) Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. Anal Biochem 356:76-85